Bone/Mineral Metabolism News

Premature surgical menopause may increase the likelihood of musculoskeletal discomfort and sarcopenia, highlighting the potential importance of hormones in postmenopausal musculoskeletal health, researchers reported in Menopause.

The FDA granted fast track designation for an investigational parathyroid hormone 1 receptor agonist to treat hypoparathyroidism, according to an industry press release.

Low bone mineral density may be a risk factor for developing cirrhosis, according to study findings published in The Journal of Clinical Endocrinology & Metabolism.

Risk for incident fracture is higher for children born to mothers with type 2 diabetes or gestational diabetes compare with those whose mothers did not have diabetes, according to data published in the Journal of Bone and Mineral Research.

The use of racial-ethnic adjustments in the U.S. version of the Fracture Risk Assessment Tool may be underestimating fractures among underrepresented groups, and new, more accurate tools are needed, according to a task force report.

Adults who undergo surgery to treat hyperparathyroidism have similar rates of fracture after surgery as healthy controls, according to data published in The Journal of Clinical Endocrinology & Metabolism.

Results showed patients who take bone mineral density-reducing medications, such as antipsychotics, serotonin reuptake inhibitors, glucocorticoids and proton pump inhibitors, may be at increased risk for revision total knee arthroplasty.

SAN FRANCISCO — A high prevalence of patients undergoing total hip arthroplasty were at high risk for osteoporosis but had a low prevalence of preoperative screening, according to results presented here.

Adults with osteoporosis who received a full course of denosumab were less likely to develop incident diabetes than those who discontinued denosumab after the initial dose, according to study data published in JAMA Network Open.

The FDA approved the first two denosumab biosimilars.